Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Nov 27;13(1):173. doi: 10.1038/s41408-023-00948-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Flow chart of inclusion of patients for propensity score matching analysis. b Treatment response of matched patients to the first course of induction treatment with VEN + HMA or standard 7 + 3. c Relapse-free survival in the matched cohorts. d Overall survival in the matched cohorts. e Mutational landscape of the unmatched 21 patients treated with VEN + HMA. Oncoprint shows mutational characteristics at diagnosis. Patients are grouped by best response after 1–2 induction cycles and are labeled with colored bars on the right. The filled bars on the right show the percentage of patients achieving CRc in the presence of each gene mutation. The asterisk indicates genes with a P < 0.05 percentage of CRc.